Today's announcement is a significant de-risking event. Of course, FDA approval is the de-risking event, and being a holder ahead of that announcement will have its rewards. Personally, I think management is performing well and shouldn't be criticised for slow pace on enrollment- that's not something they can control, and initial guidance was probably reasonable based on prior years.
Ann: ResApp Provides SMARTCOUGH-C May Study Update, page-92
Currently unlisted. Proposed listing date: 4 SEPTEMBER 2024 #
-
- There are more pages in this discussion • 52 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)